Skip to main content
Premium Trial:

Request an Annual Quote

German Start Up to Automate Novel Form of Cloning

NEW YORK, April 9 - German genomics-tool start up Sloning Biotechnology today said it has partnered with neighboring liquid-handling company Hamilton Bonaduz to commercialize its Slonomat gene synthesis robot.

 

The collaboration means that Sloning's sloning technology, which allows for the "industrial synthesis" of DNA molecules, can be fully automated.

According to Sloning, sloning can help researchers produce "any gene or large DNA molecule ... within a couple of days." The Slonomat platform, meanwhile, has the capacity of several hundred genes per year. Sloning technology differs from traditional cloning in that it "works without the need for insert restriction sites," the company said. "It allows parallel synthesis of several gene variants and shows inherent error correction."

 

The privately held company, founded in December 2001, is based just outside Munich.

The Scan

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.

Study Explores Animated Digital Message Approach to Communicate Genetic Test Results to Family Members

In the Journal of Genetic Counseling, the approach showed promise in participants presented with a hypothetical scenario related to a familial hereditary breast and ovarian cancer syndrome diagnosis.

Computational Tool Predicts Mammalian Messenger RNA Degradation Rates

A tool called Saluki, trained with mouse and human messenger RNA data, appears to improve mRNA half-life predictions by taking RNA and genetic features into account, a Genome Biology paper reports.

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.